This site is intended for healthcare professionals
Drug information

Montelukast

POM
Read time: 15 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Montelukast 10mg Film-coated Tablets are indicated in the treatment of asthma as add-on therapy in those patients 15 years of age and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting β-agonists provide inadequate clinical control of asthma. In those asthmatic patients 15 years of age and older in whom Montelukast 10mg Film-coated Tablets are indicated in asthma, Montelukast 10mg Film-coated Tablets can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast 10mg Film-coated Tablets are also indicated in the prophylaxis of asthma in patients 15 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).